Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
Recruiting
Phase 2
Interventional Study
Sickle Cell Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 18 – 21
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 40 (estimated)
- Sponsor
- St. Jude Children's Research Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
There is limited information on what causes injury to the heart in individuals with Sickle Cell Disease (SCD). Researchers in this study want to see if decreased blood flow to the heart during stress could be causing the heart damage seen in SCD patients. They also want to test people who don't have SCD to see if their hearts react the same way under stress.
Primary Objective
* To estimate the c…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria - Stratum A: Sickle cell patients with diastolic dysfunction
* 18 to 21 years of age
* Black
* Diagnosis of SCD of HbSS and HbSβ0thalassemia genotypes
* Three or more abnormal diastolic parameters (based on guidelines by American Society of echocardiography)
Inclusion Criteria -…
Contacts